Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants (PNIRS in VLBWI)
Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants: a Pilot Study
This study will look at whether a monitoring method called near-infrared spectroscopy (NIRS), can help assess lung disease in premature babies.
The main aim of this study is to describe lung oxygen levels measured by NIRS in premature babies with respiratory distress syndrome (RDS) during the first 72 hours after birth. The study will include babies born at or before 32 weeks of pregnancy who need continuous positive airway pressure (CPAP) for RDS. The study will also assess whether these lung oxygen measurements can help predict which babies will need surfactant treatment, and whether they can predict which babies may need more than one dose of surfactant.
The study will also compare lung NIRS measurements with other ways of assessing breathing problems, including lung ultrasound scores and oxygen-related measurements. In addition, the researchers will compare lung oxygen measurements with brain oxygen measurements. They will also look at whether surfactant treatment changes oxygen levels in the lungs and brain. Information from routine vital signs, such as heart rate, breathing rate, and oxygen saturation, will also be studied to see whether these measurements can help predict the need for surfactant.
Added to this researchers will look at the hemodynamics of surfactant administration by seeing how the heart and blood vessels react to surfactant administration
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Aim: To determine pulmonary regional oxygen saturation (prSO2) in preterm infants (≤32 weeks) with respiratory distress syndrome (RDS) requiring continuous positive airway pressure (CPAP) with or without surfactant replacement therapy (SRT)
Objectives:
Primary: Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life. Secondary: (1) Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS, (2) Evaluate the ability of prSO2 to predict the need for repeat surfactant administration in preterm infants with RDS, (3) Determine correlation between prSO2, lung ultrasound (LUS) scores and oxygenation indices.
Tertiary: (1) Determine the correlation between prSO2 and cerebral oxygenation (crSO2), (2) Determine the effect of surfactant administration on prSO2 and crSO2, (3) longitudinal analyses of vital signs (HR, SpO2, NIRS, oxygenation indices) to predict SRT, (4) determine the hemodynamic effects of SRT (longitudinal correlation of NIRS, haemodynamic parameters)
This will be an investigator-initiated, prospective, observational trial.
Preterm infants born at a gestational age ≤ 32 weeks will be recruited from a single neonatal center, Tygerberg Hospital, Cape Town, South Africa.
All preterm infants ≤ 32 weeks and/ or ≤1800g will be eligible for enrollment
Study Procedures
Recruitment and enrollment processes Infants will be screened within the first 3 hours after birth. Infants meeting enrollment criteria will be placed on study monitoring devices upon arrival in the neonatal unit, if meeting eligibility criteria.
Randomization/ blinding No randomization will occur in this study. Blinding is not possible due to visible monitoring equipment. Treating clinicians will however be directed not to use the monitors for any decision-making regarding patient management.
Monitoring Devices
-
Near-infrared spectroscopy will be performed using INVOS 5100c (Medtronics, Minneapolis, MN, USA) with 2 transducers, will be used that allows monitoring of 4 regions of interest. In this study 3 regional saturations will be monitored - pulmonary (left and right) and cerebral
- Pulmonary NIRS - Pulmonary sensors will be placed in a horizontal position at the 4th intercostal space area (nipple line) on the left and right hemithorax
- Cerebral NIRS - Cerebral sensor will be placed on the right of the forehead
-
Vital sign monitoring: Synchronized vital signs (heart rate (HR), respiratory rate (RR), peripheral oxygen saturation (SpO2) (Nellcor) will be monitored using a multi-parameter monitor (Mindray UMEC15, Shenzhen, China).
-
Non-invasive cardiac output monitoring: Haemodynamic monitoring will occur using the ICON Core from Osypka Medical. This provides non-invasive monitoring of numerous haemodynamic parameters, including cardiac output, stroke volume, systemic vascular resistance, cardiac contractility and thoracic fluid content. ICON sensors will be placed in standard positions on the forehead, neck arm and leg for monitoring.
Intervention procedures
1. Ultrasound:
- Lung ultrasound (LUS) will be performed after placement of the NIRS (within the first 6 hours of life) and daily. LUS will also be performed prior to any SRT. alculated. Video-clips will be stored and reviewed by blinded co-investigators.
- Cranial ultrasound (CUS) will be performed on day 1,2 and 3 to monitor for any intraventricular haemorrhage as well as to measure cerebral blood flow velocities, which may affect crSO2 values.
- Point-of-care echocardiography (POC-echo) will be performed to determine cardiac function, cardiac output, and the presence of a patent ductus arteriosus, size, flow velocity and pattern, which may affect prSO2 and crSO2 values. Standard echocardiography techniques will be used and will be performed daily on day 1,2 and 3 of life.
Trial duration
The trial will start enrolling 1 November 2026 or when all procedures have been completed. Trial will be completed when 100 participants have been recruited.
Discontinuation of study intervention
Monitoring of the infant will stop, and sensors will be removed if:
- Requested by mother
- Requested by treating clinician
- Thoracic intervention required (e.g. intercostal drainage for pneumothorax)
- Surgery required (e.g. laparotomy for focal intestinal perforation)
- Sensors interfere with medical management
Withdrawal from study
At any time point the mother or treating clinician may request withdrawal of the infant from the study, for any reason, whether for personal choice (by the mother), safety considerations or administrative reasons. Monitoring of the infant will be stopped immediately, and no further data will be collected. However, the infant will remain in the study for data analyses and outcome and clinical measure collection, unless the mother specifically requests that their infant's data not be included. Withdrawal of the infant from the study, irrespective of reason, will not influence the continued management of the infant and they will continue to receive management as per protocols in the institution.
Duration of study participation
Study participation for each infant is:
- Initiated within the first 3 hours of life
- Monitoring until 72 hours after birth
- Follow up from 72 hours until final discharge from hospital or in-hospital death.
Infants who are transferred to other institutions will be followed up for length of stay as well as neonatal respiratory complications (length of respiratory support, bronchopulmonary dysplasia, death)
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Lizelle Van Wyk, PhD
- Telefonnummer: +27219389506
- E-Mail: lizelle@sun.ac.za
Studienorte
-
-
-
Cape Town, Südafrika, 7530
- Rekrutierung
- Tygerberg Hospital
-
Kontakt:
- Lizelle Van Wyk, PhD
- Telefonnummer: 6058 +27219384911
- E-Mail: lizelle@sun.ac.za
-
Kontakt:
- Pierre Goussard, PhD
- Telefonnummer: +27219389506
- E-Mail: pgouss@sun.ac.za
-
Hauptermittler:
- Lizelle Van Wyk, PhD
-
Unterermittler:
- Pierre Goussard, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
All preterm infants 27-32 weeks born at Tygerberg Hospital, Cape Town, South Africa will be elligible for enrollment
Beschreibung
Inclusion Criteria:
- Preterm infant ≤ 32 weeks gestational age and/ or birth weight ≤ 1800g
- Infant diagnosed with respiratory distress syndrome requiring CPAP after birth
- Infant born at the research institution
Exclusion Criteria:
- Infants ≤ 26 weeks gestational age or <750g
- Infants with other causes of respiratory distress
- Infants with antenatal or postnatally diagnosed structural pulmonary abnormalities
- Infants with known or suspected chromosomal abnormalities
- Infants with other congenital structural abnormalities that may require surgery in the first 72 hours after birth
- Infants with known or suspected congenital infections including congenital syphilis, cytomegalovirus or toxoplasmosis
- Infants intubated after birth or requiring intubation and invasive ventilation immediately after birth
- Infants with a 5-minute Apgar ≤ 5
- Instillation of surfactant prior to enrollment
- Infants not expected to survive the first 72 hours after birth
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
CPAP only
Infants receiving CPAP only |
Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position |
|
SRT
Infants receiving CPAP plus surfactant |
Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PRSO2 values
Zeitfenster: 72 hours
|
Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life |
72 hours
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
SRT prediction
Zeitfenster: 72 hours
|
Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS |
72 hours
|
|
Compare prSo2 & lung ultrasound between groups
Zeitfenster: 72 hours
|
Determine correlation between prSO2 and lung ultrasound (LUS) scores between groups |
72 hours
|
|
Compare prSo2 & OSI between groups
Zeitfenster: 72 hours
|
Determine correlation between prSO2 and OSI between groups |
72 hours
|
|
Compare prSo2 & SOPI between groups
Zeitfenster: 72hrs
|
Determine correlation between prSO2 and SOPI between groups |
72hrs
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PRSO2/CUS
Zeitfenster: 72hours
|
Determine the correlation between prSO2 and cerebral oxygenation (crSO2) between groups |
72hours
|
|
Longitudinal analysis SOPI
Zeitfenster: 72 hours
|
longitudinal comparison of SOPI between groups |
72 hours
|
|
Longitudinal OSI
Zeitfenster: 72 hours
|
longitudinal comparison of OSI between groups |
72 hours
|
|
Longitudinal thoracic fluid content (TFC)
Zeitfenster: 72 hours
|
longitudinal comparison of TFC between groups |
72 hours
|
|
Longitudinal CI
Zeitfenster: 72 hours
|
longitudinal comparison of cardiac index between groups |
72 hours
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Dani C, Miselli F, Zini T, Scarponi D, Luzzati M, Sarcina D, Fusco M, Dianori F, Berardi A. Measurement of lung oxygenation by near-infrared spectroscopy in preterm infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 2024 Jun;59(6):1631-1637. doi: 10.1002/ppul.26955. Epub 2024 Mar 5.
- Ozdemir FE, Alan S, Aliefendioglu D. The diagnostic value of pulmonary near-infrared spectroscopy in the early distinction of neonatal pneumonia from transient tachypnea of the newborn. Pediatr Pulmonol. 2023 Nov;58(11):3271-3278. doi: 10.1002/ppul.26656. Epub 2023 Aug 30.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 32886
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Patient data, as per SUN HREC guidelines, can only be shared upon an agreed upon data sharing agreement
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .